BMS's stake in Medarex closes in on 90%
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has completed its initial tender offer for shares of Medarex. Approximately 87.7% of Medarex's stock, or 119 million shares, have been tendered.